Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 20:2020:7638975.
doi: 10.1155/2020/7638975. eCollection 2020.

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

Junming Peng  1 , Hongtao Jiang  1 , Jinan Guo  1 , Jiansheng Huang  1 , Qian Yuan  1 , Jing Xie  1 , Kefeng Xiao  1
Affiliations

CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD

Junming Peng et al. Biomed Res Int. .

Abstract

Purpose: CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily. Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors. However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.

Methods: The study included 159 patients with BC and 68 healthy controls. The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC). Western blotting was performed to detect the expression of proteins in BC cells. The relationship between CD147 and GSDMD was analyzed by the IHC score.

Results: The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen. In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation. Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation. BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.

Conclusion: These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
IHC analysis of CD147 and Ki-67 expression in bladder cancer. (a, d) IHC was performed to detect CD147 and Ki-67 expression in clinical sample from bladder cancer and healthy control. Scale bar, 50 m. (b–e) Statistical analysis of mean density of CD147 expression in the indicated group by t-test, ∗∗p < 0.01. (f) Clinical association analysis was performed between CD147 and GSDMD.
Figure 2
Figure 2
CD147 regulates GSDMD expression in BC. (a) IHC was used to analyze CD147 and GSDMD expression in various stages of bladder cancer tissue, and (b, c) WB was performed to detect the effect of CD147 on GSDMD and Ki-67 expression in the indicated group. (d) CCK-8 assay was employed to detect cell proliferation in the indicated group. (e) TCGA analysis of positive association between CD147 and GSDMD.
Figure 3
Figure 3
CD147 is a worse prognostic factor for mortality in BC patients. a and b represent the Kaplan–Meier analysis of DFS (a) and OS (b) in BC patients according to CD147 expression from TCGA dataset. (c) Survival rate was analyzed in 159 subjects classified into two groups based on CD147 expression, p=0.041.
See this image and copyright information in PMC

References

    1. Zhang G., Wang Q., Yang M., et al. A web server for investigating prognostic biomarkers of bladder cancer patients. Frontiers in Oncology. 2019;9:p. 466. doi: 10.3389/fonc.2019.00466. - DOI - PMC - PubMed
    1. Sjödahl G., Eriksson P., Liedberg F., Höglund M. Molecular classification of urothelial carcinoma: global mrna classification versus tumour-cell phenotype classification. The Journal of Pathology. 2017;242(1):113–125. doi: 10.1002/path.4886. - DOI - PMC - PubMed
    1. Shen T., Yang L., Zhang Z., et al. Kif20a affects the prognosis of bladder cancer by promoting the proliferation and metastasis of bladder cancer cells. Disease Markers. 2019;2019:9. doi: 10.1155/2019/4863182.4863182 - DOI - PMC - PubMed
    1. Piao X.-M., Byun Y. J., Kim W.-J., Kim J. Unmasking molecular profiles of bladder cancer. Investigative and Clinical Urology. 2018;59(2):72–82. doi: 10.4111/icu.2018.59.2.72. - DOI - PMC - PubMed
    1. Nabeshima K., Iwasaki H., Koga K., Hojo H., Suzumiya J., Kikuchi M. Emmprin (basigin/cd147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathology International. 2006;56(7):359–367. doi: 10.1111/j.1440-1827.2006.01972.x. - DOI - PubMed

MeSH terms